Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 6,866.00
Bid: 6,864.00
Ask: 6,867.00
Change: 9.00 (0.13%)
Spread: 3.00 (0.04%)
Open: 6,800.00
High: 6,921.00
Low: 6,779.00
Yest. Close: 6,857.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

LONDON MARKET MIDDAY: Stocks Rise On Expectation Of Dovish Draghi

LONDON (Alliance News) - Stocks in London were mixed Thursday at midday, with large- and mid-cap indices firmly in the green as investors anticipate a dovish outlook from Europe's central In a

6 Jun 19 12:15

WINNERS & LOSERS SUMMARY: Rolls Royce And L&G Rise On Pension Pact

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Thursday.----------FTSE 100 - WINNERS----------Rolls up

6 Jun 19 10:47

AstraZeneca leukaemia drug meets trial end-point

(Sharecast News) - AstraZeneca said on Thursday its Calquence leukaemia drug had met the primary endpoint of a phase 3 trial and would allow it to file for regulatory approval later this year.

6 Jun 19 08:34

TOP NEWS: AstraZeneca Leukaemia Study Meets Primary Endpoint

LONDON (Alliance News) - AstraZeneca PLC on Thursday reported positive results from its trial of Calquence in patients with chronic lymphocytic leukaemia, a type of blood cancer.The FTSE of

6 Jun 19 08:17

Tuesday broker round-up

(Sharecast News) - NewRiver: Berenberg downgrades to hold with a target price of 248p.

4 Jun 19 13:55

AstraZeneca searching for successor to chairman Johansson, reports say

(Sharecast News) - AstraZeneca has begun the search for a new chairman as the role's current incumbent Leif Johansson looks set to end his seven year spell at the Anglo-Swedish outfit, according to a report from Sky News.

4 Jun 19 09:11

AstraZeneca's Lynparza Response Rate Beats Chemotherapy In Trial

LONDON (Alliance News) - AstraZeneca PLC on Tuesday said its Lynparza drug produced a higher objective response rate than chemotherapy in advanced ovarian cancer and improved progression-free a of

4 Jun 19 08:28

CORRECT (Jun 3): AstraZeneca Cancer Drugs Have Positive Trial Results

(Correcting that AstraZeneca presented two-year progression free survival data from its Polo trial not three-year overall survival data and that 10% of patients on placebo in the Lynparza trial no

4 Jun 19 07:23

LONDON MARKET CLOSE: Mixed Close Amid Heightening Trade Tensions

LONDON (Alliance News) - Stocks in London saw a mixed close on Monday despite trade tensions between the US, China and Mexico continuing to heat up, as well as disappointing manufacturing data.The

3 Jun 19 16:57

Monday broker round-up

(Sharecast News) - Ferguson: Peel Hunt upgrades to add with a target price of 5,430p.

3 Jun 19 12:07

Trials show AstraZeneca's Lynparza delaying pancreatic cancer progression

(Sharecast News) - AstraZeneca announced on Monday that its Lynparza pancreatic cancer drug has returned positive phase three trial results, doubling the amount of patients with no disease progression.

3 Jun 19 07:46

TOP NEWS: Two AstraZeneca Cancer Drugs Have Positive Trial Results

LONDON (Alliance News) - AstraZeneca PLC on Sunday announced encouraging results from phase three trials of its cancer drugs Lynparza and Imfinzi.The drug maker presented three-year overall

3 Jun 19 07:32

Friday broker round-up

(Sharecast News) - SafeChange International Group: Berenberg downgrades to hold with a target price of 436p.

24 May 19 13:23

AstraZeneca's Symbicort Turbuhaler Reduces Asthma Attacks In New Trial

LONDON (Alliance News) - AstraZeneca PLC's Novel Start trial for its Symbicort Turbuhaler demonstrated a reduction in the rate of asthma attacks in patients with mild asthma compared to common

20 May 19 08:21

AstraZeneca To Present Positive Data On Lynparza And Imfinzi Trials

LONDON (Alliance News) - AstraZeneca PLC said Thursday said it will present positive data from phase three trials of cancer drugs Lynparza and Imfinzi at the 2019 American Society of Clinical from

16 May 19 10:45

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.